Is Pfizer (PFE) overvalued or fairly valued?

MarketChacha shows Pfizer's valuation in context — a trailing P/E of about 11.8, a forward P/E of about 8.8, a price-to-book of about 1.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Pfizer's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.85×) from reported figures — education, not a rating.

What is Pfizer's revenue?

Pfizer reported revenue of $62.6B for FY2025, with net profit of $7.8B, per official filings.

What is the share price of Pfizer (PFE)?

Pfizer last traded at $25.01 (+0.4% on the day), as of 7/31/2026 — a delayed quote shown for education, not investment advice.

Pfizer

PFE · NYSE · Pharma · United States

Snapshot

TickerPFE

ExchangeNYSE

SectorPharma

IndustryDrug Manufacturers - General

CountryUnited States

Employees75,000

HeadquartersNew York, United States

Websitewww.pfizer.com

Filings tracked14

About Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Who owns it

Insiders0.1%
Institutions69.5%
Public & other30.4%

3,661 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.74%
Vanguard Capital Management LLC6.48%
State Street Corporation5.29%
Geode Capital Management, LLC2.34%
Vanguard Portfolio Management LLC2.05%
Fisher Asset Management, LLC1.84%
Morgan Stanley1.63%
Northern Trust Corporation1.09%

Largest institutional holders — last updated 3/31/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.85×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend4.2% → 12.4%

Margin has expanded by about 8.3 points — the business is getting more profitable.

Growth qualityrev 11% · PAT 92%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $16.1B · EPS 0.81

Est. earnings growth -6.8%

Next fiscal year

Rev $59.4B · EPS 2.83

Est. earnings growth -3.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$62.6B

Net margin

12.4%

ROE

9.0%

Revenue CAGR (2y)

+10.9%

Profit CAGR (2y)

+91.5%

EPS (FY2025)

1.36

Net profit (FY2025)

$7.8B

Ask MarketChacha about PFE

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

On MarketChacha

Posts about PFE

Pfizer just filed an 8-K: what its CFO exit meansc/usmarkets · 6/18/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$62.6B	$7.8B	1.36	12.4%	9.0%
FY2024	$63.6B	$8.0B	1.41	12.6%	9.1%
FY2023	$50.9B	$2.1B	0.37	4.2%	2.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$14.5B	$2.7B	0.47	18.6%
2025Q3	$16.7B	$3.5B	0.62	21.3%
2025Q2	$14.7B	$2.9B	0.51	19.9%
2025Q1	$13.7B	$3.0B	0.52	21.6%
2024Q3	$17.7B	$4.5B	0.78	25.2%
2024Q2	$13.3B	$41.0M	0.01	0.3%
2024Q1	$14.9B	$3.1B	0.55	20.9%
2023Q4	$13.5B	$-2.4B	-0.42	-17.7%
2023Q3	$13.0B	$2.3B	0.41	17.9%
2023Q2	$18.5B	$5.5B	0.97	30.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Exhibits
SEC6/18/2026material
8-K — Reg FD disclosure
SEC6/18/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Shareholder vote results
SEC4/27/2026material
10-K filing
SEC2/26/2026
8-K — Results of operations, Exhibits
SEC2/3/2026material

2025

8-K — Reg FD disclosure, Exhibits
SEC12/16/2025material
8-K — Other events, Exhibits
SEC11/21/2025material
8-K — Other events
SEC11/13/2025material
8-K — Results of operations, Exhibits
SEC11/4/2025material
10-Q filing
SEC11/4/2025
8-K — Results of operations, Exhibits
SEC8/5/2025material
10-Q filing
SEC8/5/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.